ABSTRACT

Purpose: In some patients who receive adjuvant radiotherapy (RT) for the left breast, the stomach is located inside the RT field. This study investigates the incidence of gastric complications following adjuvant RT for breast cancer using data of the Health Insurance Review and Assessment Service in South Korea.

Methods: We identified 37,966 women who underwent surgery and received adjuvant RT for breast cancer. The cumulative incidence rate of gastric hemorrhage and gastric cancer was calculated and compared for left and right breast cancers.

Results: Among 37,966 patients, 19,531 (51.4%) and 18,435 (48.6%) had right and left breast cancers, respectively. After a median follow-up duration of 6.3 years, the cumulative incidence of gastric cancer and gastric hemorrhage did not differ between right and left breast cancers ($p = 0.414$ and $p = 0.166$, respectively). The multivariable analysis revealed that old age was the only factor associated with the development of gastric cancer ($p < 0.001$) and gastric hemorrhage ($p < 0.001$). The incidence of gastric cancer and hemorrhage did not differ between patients who received adjuvant RT for right and left breast cancers.

Conclusion: Irradiation-related chronic complications of the stomach in patients with breast cancer are minimal. A study with a longer follow-up duration might be needed to assess the risk of gastric cancer.

Keywords: Breast neoplasms; Gastrointestinal hemorrhage; Radiotherapy; Stomach neoplasms

INTRODUCTION

Breast cancer is the most common cancer in women worldwide and the second most common malignancy in Korean women [1,2]. Breast-conserving surgery and adjuvant radiotherapy (RT) are increasingly performed in patients with breast cancer [2,3]. Accordingly, post-RT complications are of great interest for both physicians and patients. Late cardiac complications following adjuvant RT for the left breast have been widely investigated, and a linear association between heart dose and coronary heart disease was identified in a large population-based study [4].
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Author Contributions
Conceptualization: Cho WK, Choi DH, Park W, Kim H, Kim S, Shin MH, Cha H; Data curation: Cho WK; Formal analysis: Cho WK, Kim S; Funding acquisition: Choi DH; Investigation: Cho WK, Shin MH; Methodology: Cho WK, Kim S, Shin MH; Project administration: Cho WK; Resources: Park W; Software: Cho WK, Kim S; Supervision: Park W, Kim H; Visualization: Cho WK; Writing - original draft: Cho WK; Writing - review & editing: Choi DH, Park W, Kim H, Kim S, Shin MH, Cha H.

The ipsilateral lung and heart are the normal organs of concern when planning for whole breast RT. However, other normal organs such as the stomach, liver, and colon are also frequently irradiated, depending on individual anatomy. The stomach is located directly below the left diaphragm and occasionally included in the tangential RT field in left breast cancer treatment. However, little is known about the effect of irradiation on the stomach following adjuvant RT for breast cancer. Although the stomach is considered relatively safe to irradiate, we hypothesized that several factors predisposing to gastric disease in the Korean population may enhance RT-related toxicities of the stomach.

This study aimed to evaluate late complications in the stomach following adjuvant RT for breast cancer using data from the Health Insurance Review and Assessment Service (HIRA) of South Korea.

METHODS

Database and study population
The Institutional Review Board of Samsung Medical Center approved this study and informed consent was waived. (IRB No. 2017-06-019).

A nationwide cohort diagnosed with breast cancer (C50.* according to the International Classification of Disease Tenth Revision [ICD-10]) from 2007 to 2017 was extracted from the HIRA database. Figure 1 describes the process of selecting the study population. After excluding women who were already diagnosed with other cancers prior to breast cancer and those aged < 20 years, 225,477 women were identified. Among these, patients who underwent curative surgery for breast cancer followed by adjuvant RT were identified (n = 109,894). To secure ≥ 5 years of follow-up, the cohort who underwent RT in 2012 was selected and followed until 2017 for development of gastric complications. Right and left breast cancers were identified using breast cancer codes: right breast (C50.*0) and left breast (C50.*1). Cases with unknown tumor laterality and both right and left breast codes were excluded. Finally, a total of 37,966 patients were included in the analysis.

Gastric complications
Gastric complications were assessed by the identifying diagnosis of gastric cancer and hemorrhagic gastric disease from the date of RT until December 2017, and the incidences between right and left breast cancers were compared. The diagnosis of gastric cancer was defined as C16.* codes in the claim data, and the diagnosis of hemorrhagic gastric disease was defined as diagnostic codes of K25.0, K25.1, K25.2, K25.4, K25.5, K25.6, K26.0, K26.1, K26.2, K26.4, K26.5, K26.6, K27.0, K27.1, K27.2, K27.4, K27.5, K27.6, K28.0, K28.1, K28.2, K28.4, K28.5, K28.6, K29.0, K92.0, K92.1, and K92.2 in ICD-10 [5]. Supplementary Table 1 shows detailed information regarding claim codes for surgery and RT.

Statistical analysis
Distributions of categorical variables between right and left breast cancers were compared using the chi-square test. Time to disease was defined as the time between the last day of RT for breast cancer and the date of the first disease claim. To estimate the cumulative incidence of gastric disease and generate hazard plots, the Kaplan-Meier method was used. The cumulative incidence curves between groups were compared using log-rank test. Cox proportional-hazards model was used to estimate hazard ratios (HRs) and 95% confidence intervals.
intervals (CIs) to control for other covariates. All statistical analysis was conducted using SAS software version 9.4 (SAS Institute, Cary, USA).

RESULTS

Patient characteristics
A total of 37,966 patients were included in the analysis. Of a total of 37,966 patients, 19,531 (51.4%) had right breast cancer, and 18,135 (48.6%) had left breast cancer. The most frequent age was 41–50 years (n = 15,765, 41.5%), which was followed by 51–60 years (n = 10,332, 27.2%), < 40 years (n = 6,617, 17.4%), and > 60 years (n = 5,252, 13.8%). Chemotherapy was performed in 62.3% of all patients. The distributions of chemotherapy are presented in Table 1.

Gastric cancer
After a median follow-up duration of 6.3 years (range, 0–10.5), 236 patients developed gastric cancer, and the 10-year cumulative incidence was 0.85% (Figure 2A). The cumulative incidence of gastric cancer did not differ between right and left breast cancers (0.81% vs. 0.89% at 10 years, \(p = 0.414\)). The incidence of gastric cancer at 10 years was 0.30%, 0.77%, 1.01%, and 1.53% in patients aged ≤ 40 years, 41–50 years, 51–60 years, and > 60 years, respectively (Figure 2B). From the mutually adjusted Cox proportional-hazards model that
included the age group, chemotherapy, and tumor laterality, old age was the only significant factor for the development of gastric cancer \( (p < 0.001) \) (Table 2). The HRs (95% CI) for gastric cancer in patients aged 41–50 years, 51–60 years, and > 60 years compared to those aged ≤ 40 years were 2.23 (1.33–3.76), 2.77 (1.63–4.71), and 4.84 (2.82–8.33), respectively.

Table 2. Adjusted cox regression models for gastric complications

| Characteristics | Gastric cancer | Hemorrhagic gastritis |
|----------------|---------------|----------------------|
|                | Hazard ratio* (95% CI) | \( p^* \) | Hazard ratio* (95% CI) | \( p^* \) |
| **Age**        |               |                     |                       |               |
| ≤ 40           | Reference     | 0.002               | Reference             | 0.14         |
| 41–50          | 2.24 (1.33–3.76) | < 0.001             | 1.14 (0.96–1.37)      | 0.14         |
| 51–60          | 2.77 (1.63–4.71) | < 0.001             | 1.28 (1.07–1.55)      | 0.009        |
| > 60           | 4.84 (2.82–8.33) | < 0.001             | 1.54 (1.25–1.89)      | < 0.001      |
| **Chemotherapy** |               |                     |                       |               |
| Yes            | Reference     | 0.24               | Reference             | 0.81         |
| No             | 1.18 (0.90–1.54) | 0.99 (0.87–1.11)   |                       |               |
| **Laterality** |               |                     |                       |               |
| Right          | Reference     | 0.36               | Reference             | 0.15         |
| Left           | 0.89 (0.69–1.15) | 0.92 (0.82–1.03)  |                       |               |

*Hazard ratios and \( p \)-values were calculated with the use of Cox regression method.
After excluding 5,121 patients who had gastric disease before the diagnosis of breast cancer, 2,936 of 29,909 patients developed hemorrhagic gastric disease after RT, and the 5-year cumulative incidence rate of gastric hemorrhage was 2.5%. The cumulative incidence of hemorrhagic gastric disease was not different between right and left breast cancers (2.6% vs. 2.4% at 5 years, \( p = 0.166 \), Figure 3A). The 5-year incidence rates of hemorrhagic gastric disease were 2.16%, 2.37%, 2.51%, and 3.08% in patients aged ≤ 40 years, 41 –50 years, 51–60 years, and > 60 years, respectively (Figure 3B). In the multivariable analysis, old age was the only significant factor (\( p < 0.001 \)) (Table 2). The HRs (95% CI) for hemorrhagic gastric disease in patients aged 41–50 years, 51–60 years, and > 60 years compared to women aged ≤ 40 years were 1.14 (0.96–1.37), 1.28 (1.07–1.55), and 1.54 (1.25–1.89), respectively.

**DISCUSSION**

This study demonstrated that the risk of late gastric complications following adjuvant RT was not different between patients with right and left breast cancers and age was the most important risk factor for the development of gastric complications. In the Korean insurance system, most patients with cancer complete the regular follow-up at 5 years and thereafter visit local hospitals because patient costs increase 5 years after initiating cancer treatment if there is no evidence of recurrence. Accordingly, most information on late complications that develop after 5 years might be lost if hospital data is used. To overcome this issue, we used the data of the National Health Insurance system of South Korea, which covers > 98% of the Korean population [6].

The stomach is a relatively radioresistant organ, and the estimated dose with 5% risk at 5 years (TD 5/5) for the whole stomach is reported to be 50 Gy [7]. The rate of gastric ulcer was 4% after a dose < 50 Gy vs. 16% after a dose ≥ 50 Gy in early studies [8]. Considering standard doses of adjuvant RT for breast cancer (50.4–54 Gy), the dose to the stomach would not be negligible if > 90% of the prescribed dose is irradiated to the stomach. Similar to...
radiation proctitis, RT-induced hemorrhagic gastric disease usually presents within 3 years of RT. It manifests as an edematous change in the mucosa and multiple telangiectasias in the irradiated area, resulting in hemorrhage [9]. RT-induced hemorrhagic gastric disease has been reported in a few case reports, most of which were from gastrointestinal malignancy cases [10-14]. Das et al. [10] reported nine cases of gastric bleeding following RT for intrahepatic cholangiocarcinoma and suggested that the risk of RT-related gastric bleeding was most relevant to $V_{40}$ and $V_{50}$ of the stomach. Feng et al. [11] showed that RT-induced gastric bleeding is largely affected by concomitant liver cirrhosis and maximal stomach dose. A generalized equivalent uniform dose (gEUD) of 46 Gy is associated with a 20% bleeding risk in patients without cirrhosis, while a gEUD of only 18 Gy is associated with a 20% bleeding risk in patients with cirrhosis [11]. Other than cirrhosis, old age, concurrent chemotherapy, and Helicobacter pylori-induced gastritis were reported as risk factors that can lower the threshold dose of the stomach [15]. In the present study, age was the only significant risk factor for hemorrhagic gastric disease.

Korea has an epidemic of gastric cancer due to $H. pylori$ infection and high consumption of spicy and salty food. In the Korean female population, the crude incidence rates of gastric cancer are 0.04%, 0.09%, and 0.17% for those aged 40–54 years, 55–69 years, and 70–79 years, respectively [16]. Surveillance, Epidemiology, and End Results data showed that the incidence rates of gastric cancer in patients with breast cancer were 0.14% and 0.08% in the surgery-alone and surgery plus RT groups, respectively [17]. Another Western study [18] reported that the incidence rates of stomach cancer were 0.22% and 0.16% in those who received and did not receive RT for breast cancer, respectively. A small Korean study reported that 0.6% of 2657 patients with breast cancer developed gastric cancer, which is similar with our result (0.62%) [19]. Another Korean study reported a much lower incidence rate of gastric cancer (0.29%) among breast cancer survivors [20]. The lower rates might be due to loss of diagnosis outside the hospital. The incidence rate of gastric cancer in Korean patients with breast cancer who received RT is higher than that of the general Korean population or patients with breast cancer in Western countries. However, the incidence did not differ between patients with right and left breast cancers.

This study has several limitations. First, a number of important confounding factors for gastric disease were not considered, such as $H. pylori$ infection, smoking, and alcohol consumption. Unfortunately, HIRA data could not be linked to hospital or personal data. Second, the claim data contain some intentional or unintentional errors induced by reimbursement issues or physician priorities. Furthermore, it is difficult to identify the causal effect of RT on diseases through detailed information such as comparison between endoscopic finding and RT field, especially with hemorrhagic gastric disease. Nevertheless, we hypothesized that claim-related errors and other clinical factors such as $H. pylori$ infection, smoking history, and medication use would be the same in right and left breast cancers, so we compared the two groups even with the possibility of these errors. Finally, there was no difference between right and left breast cancers in the development of hemorrhagic gastric disease or gastric cancer, indicating that RT does not further increase the risk of these diseases. However, crossed incidence curves of right and left breast cancers for gastric cancer development at 10 years suggest that a longer follow-up period might be needed because RT-related secondary malignancy usually develops in approximately 10 years.

Therefore, we did not find any increased risk of gastric cancer and hemorrhagic gastric disease in patients who received adjuvant RT for left breast cancer compared to those for
right breast cancer in the 10-year follow-up. The RT-related chronic complications of the stomach in patients with breast cancer are minimal. A study with longer follow-up duration is needed to confirm the risk of gastric cancer in these patients.

SUPPLEMENTARY MATERIAL

Supplementary Table 1
Detailed information regarding claim codes for surgery and radiotherapy

Click here to view

REFERENCES

1. Yang TJ, Morrow M, Modi S, Zhang Z, Krause K, Siu C, et al. The effect of molecular subtype and residual disease on locoregional recurrence in breast cancer patients treated with neoadjuvant chemotherapy and postmastectomy radiation. Ann Surg Oncol 2015;22 Suppl 3:S495-501.

2. Jung KW, Won YJ, Kong HI, Lee ES; Community of Population-Based Regional Cancer Registries. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2015. Cancer Res Treat 2018;50:303-36.

3. Kang SY, Kim YS, Kim Z, Kim HY, Lee SK, Jung KW, et al. Basic findings regarding breast cancer in Korea in 2015: data from a breast cancer registry. J Breast Cancer 2018;21:1-10.

4. Darby SC, Ewertz M, McGale P, Bennett AM, Blom-Goldman U, Bronnum D, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013;368:987-98.

5. Kim J, Lee J, Shin CM, Lee DH, Park BJ. Risk of gastrointestinal bleeding and cardiovascular events due to NSAIDs in the diabetic elderly population. BMJ Open Diabetes Res Care 2015;3:e000133.

6. Kwon S. Thirty years of national health insurance in South Korea: lessons for achieving universal health care coverage. Health Policy Plan 2009;24:63-71.

7. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21:109-22.

8. Brick IB. Effects of million volt irradiation on the gastrointestinal tract. AMA Arch Intern Med 1955;96:26-31.

9. Kavanagh BD, Pan CC, Dawson LA, Das SK, Li XA, Ten Haken RK, et al. Radiation dose-volume effects in the stomach and small bowel. Int J Radiat Oncol Biol Phys 2010;76:S101-7.

10. Das P, Abboud MT, Haque W, Javel M, Kaseb A, Curley SA, et al. Gastric bleeding after radiation therapy for intrahepatic cholangiocarcinoma. Pract Radiat Oncol 2013;3:344-8.

11. Feng M, Normolle D, Pan CC, Dawson LA, Amarnath S, Ensminger WD, et al. Dosimetric analysis of radiation-induced gastric bleeding. Int J Radiat Oncol Biol Phys 2012;84:e1-6.

12. Zhang L, Xie XY, Wang Y, Wang YH, Chen Y, Ren ZG. Treatment of radiation-induced hemorrhagic gastritis with prednisolone: a case report. World J Gastroenterol 2012;18:7402-4.

13. Zhang L, Xia WJ, Zhang ZS, Lu XL. Growth hormone used to control intractable bleeding caused by radiation-induced gastritis. World J Gastroenterol 2015;21:9453-6.

14. Yun HG, Kim HY, Kim DY, Lim YI. Successful treatment of intractable bleeding caused by radiation-induced hemorrhagic gastritis using oral prednisolone: a case report. Cancer Res Treat 2015;47:334-8.
15. Holyoake DL, Warren DR, Hurt C, Aznar M, Partridge M, Mukherjee S, et al. Stomach dose-volume predicts acute gastrointestinal toxicity in chemoradiotherapy for locally advanced pancreatic cancer. Clin Oncol (R Coll Radiol) 2018;30:418-26. PUBMED | CROSSREF

16. Song M, Kang D, Yang JJ, Choi JY, Sung H, Lee Y, et al. Age and sex interactions in gastric cancer incidence and mortality trends in Korea. Gastric Cancer 2015;18:580-9. PUBMED | CROSSREF

17. Berrington de Gonzalez A, Curtis RE, Gilbert E, Berg CD, Smith SA, Stovall M, et al. Second solid cancers after radiotherapy for breast cancer in SEER cancer registries. Br J Cancer 2010;102:220-6. PUBMED | CROSSREF

18. Burt LM, Ying J, Poppe MM, Suneja G, Gaffney DK. Risk of secondary malignancies after radiation therapy for breast cancer: comprehensive results. Breast 2017;35:122-9. PUBMED | CROSSREF

19. Kim JY, Song HS. Metachronous double primary cancer after treatment of breast cancer. Cancer Res Treat 2015;47:64-71. PUBMED | CROSSREF

20. Jung HK, Park S, Kim NW, Lee JE, Kim Z, Han SW, et al. Development of second primary cancer in Korean breast cancer survivors. Ann Surg Treat Res 2017;93:287-92. PUBMED | CROSSREF